Flmodafinil vs Modafinil

Flmodafinil wins for:

• Higher potency per milligram (roughly 2x modafinil in wake-promoting effect)
• Shorter duration (6–8 hours vs 12–15), making late-day protocols less likely to disrupt sleep
• Minimal CYP3A4 induction, fewer drug-drug interactions (friendlier for oral AAS, contraceptives, and polypharmacy stacks)

Modafinil wins for:

• Vastly better documentation, human studies, and decades-long track record
• Consistent effects and predictable half-life (10–15 hours clears most use cases)
• Simple sourcing through generics (Modalert, Modvigil, etc.) and bulk research suppliers
• Lower unknowns—real-world side effect profile is well-mapped vs limited flmodafinil literature

Pick Flmodafinil if:

• A tighter focus window (6–8 hours) is critical and sleep onset must be preserved
• The protocol calls for doubling or stacking with other compounds that interact with CYP enzymes (for example, oral AAS or OCs)
• There is prior sensitivity to modafinil's 12–15 hour duration or late-day aftereffects
• Non-prescription, grey-market sourcing is the only viable path
• Minimal stimulant 'push' is wanted—subjective effects are more neutral and task-oriented

Pick Modafinil if:

• Documented safety, reliability, and effect reproducibility are the top priorities
• Research calls for 10–15 hours of sustained vigilance, such as overnight or multi-shift protocols
• Study or work blocks demand max attention with minimal unknowns in pharmacokinetics
• Proven sourcing (generic tabs, established suppliers) and batch-to-batch consistency are required
• Appetite suppression is a focus in a strict cutting or contest-prep research context